Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 6/20 | 0.43 |
| ▸ | IGF1R | P08069 | 6/20 | 0.43 |
| ▸ | INSR | P06213 | 4/20 | 0.43 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 4/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | ULK1 | O75385 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12780043 | 0.86 | ZAP70 (0.52) | ALKIGF1RINSRZAP70EGFR | |
| SCHEMBL12918385 | 0.83 | IGF1R (0.45) | ALKIGF1RINSRZAP70CDK4 | |
| SCHEMBL12728527 | 0.83 | IGF1R (0.46) | ALKIGF1RINSRZAP70CDK4 | |
| SCHEMBL12728538 | 0.82 | IGF1R (0.42) | ALKIGF1RINSRZAP70EGFR | |
| SCHEMBL12892731 | 0.82 | ZAP70 (0.63) | ALKIGF1RINSRZAP70EGFR | |
| SCHEMBL12728604 | 0.82 | ALK (0.53) | ALKIGF1RINSRZAP70EGFR | |
| SCHEMBL12728606 | 0.80 | ALK (0.53) | ALKIGF1RINSRZAP70EGFR | |
| SCHEMBL12892723 | 0.78 | ZAP70 (0.54) | ALKIGF1RINSRZAP70CDK4 | |
| SCHEMBL12917670 | 0.78 | ALK (0.44) | ALKIGF1RINSRZAP70CDK4 | |
| SCHEMBL12780486 | 0.77 | ALK (0.54) | ALKIGF1RINSRZAP70AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | TYMS, TYMP, DPYD | ALK 3384/4885IGF1R 4627/4885INSR 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.